RCD regimen: Difference between revisions

Jump to navigation Jump to search
(Created page with "__NOTOC__ {{SI}} {{CMG}}; {{AE}} {{AV}} ==Overview== {{PAGENAME}} refers to a regimen consisting of rituximab, cyclophosphamide, and dexamethasone used to treat...")
 
No edit summary
 
Line 2: Line 2:
{{SI}}
{{SI}}
{{CMG}}; {{AE}} {{AV}}
{{CMG}}; {{AE}} {{AV}}


==Overview==
==Overview==
Line 9: Line 8:
==Regimen==
==Regimen==
{{chemo|R|Rituximab}}
{{chemo|R|Rituximab}}
{{chemo|C|Cyclophosphamide}}
{{chemo|C|Cyclophosphamide}}
{{chemo|D|Dexamethasone}}
{{chemo|D|Dexamethasone}}


==Indications==
==Indications==
*[[Non-Hodgkin lymphomas]].<ref name="pmid25043930">{{cite journal| author=Perry M, Delarche A, Ribes D, Vergez F, Guilbeau-Frugier C, Laurent C et al.| title=Rituximab-cyclophosphamide-dexamethasone is highly effective in patients with monoclonal Ig deposit-related glomerulopathy and indolent non-Hodgkin lymphomas. | journal=Am J Hematol | year= 2014 | volume= 89 | issue= 10 | pages= 969-73 | pmid=25043930 | doi=10.1002/ajh.23798 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=25043930 }} </ref> and [[Chronic lymphocytic leukemia]]<ref name="pmid21699387">{{cite journal| author=Michallet AS, Rossignol J, Cazin B, Ysebaert L| title=Rituximab-cyclophosphamide-dexamethasone combination in management of autoimmune cytopenias associated with chronic lymphocytic leukemia. | journal=Leuk Lymphoma | year= 2011 | volume= 52 | issue= 7 | pages= 1401-3 | pmid=21699387 | doi=10.3109/10428194.2011.591005 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21699387 }} </ref>
*[[Non-Hodgkin lymphomas]].<ref name="pmid25043930">{{cite journal| author=Perry M, Delarche A, Ribes D, Vergez F, Guilbeau-Frugier C, Laurent C et al.| title=Rituximab-cyclophosphamide-dexamethasone is highly effective in patients with monoclonal Ig deposit-related glomerulopathy and indolent non-Hodgkin lymphomas. | journal=Am J Hematol | year= 2014 | volume= 89 | issue= 10 | pages= 969-73 | pmid=25043930 | doi=10.1002/ajh.23798 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=25043930 }} </ref> and [[Chronic lymphocytic leukemia]]<ref name="pmid21699387">{{cite journal| author=Michallet AS, Rossignol J, Cazin B, Ysebaert L| title=Rituximab-cyclophosphamide-dexamethasone combination in management of autoimmune cytopenias associated with chronic lymphocytic leukemia. | journal=Leuk Lymphoma | year= 2011 | volume= 52 | issue= 7 | pages= 1401-3 | pmid=21699387 | doi=10.3109/10428194.2011.591005 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21699387 }} </ref>



Latest revision as of 19:05, 30 March 2015

WikiDoc Resources for RCD regimen

Articles

Most recent articles on RCD regimen

Most cited articles on RCD regimen

Review articles on RCD regimen

Articles on RCD regimen in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on RCD regimen

Images of RCD regimen

Photos of RCD regimen

Podcasts & MP3s on RCD regimen

Videos on RCD regimen

Evidence Based Medicine

Cochrane Collaboration on RCD regimen

Bandolier on RCD regimen

TRIP on RCD regimen

Clinical Trials

Ongoing Trials on RCD regimen at Clinical Trials.gov

Trial results on RCD regimen

Clinical Trials on RCD regimen at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on RCD regimen

NICE Guidance on RCD regimen

NHS PRODIGY Guidance

FDA on RCD regimen

CDC on RCD regimen

Books

Books on RCD regimen

News

RCD regimen in the news

Be alerted to news on RCD regimen

News trends on RCD regimen

Commentary

Blogs on RCD regimen

Definitions

Definitions of RCD regimen

Patient Resources / Community

Patient resources on RCD regimen

Discussion groups on RCD regimen

Patient Handouts on RCD regimen

Directions to Hospitals Treating RCD regimen

Risk calculators and risk factors for RCD regimen

Healthcare Provider Resources

Symptoms of RCD regimen

Causes & Risk Factors for RCD regimen

Diagnostic studies for RCD regimen

Treatment of RCD regimen

Continuing Medical Education (CME)

CME Programs on RCD regimen

International

RCD regimen en Espanol

RCD regimen en Francais

Business

RCD regimen in the Marketplace

Patents on RCD regimen

Experimental / Informatics

List of terms related to RCD regimen

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aparna Vuppala, M.B.B.S. [2]

Overview

RCD regimen refers to a regimen consisting of rituximab, cyclophosphamide, and dexamethasone used to treat monoclonal Ig deposit-related glomerulopathy and indolent non-Hodgkin lymphomas.[1] and autoimmune cytopenias associated with chronic lymphocytic leukemia.[2]

Regimen

RRituximab

CCyclophosphamide

DDexamethasone

Indications

References

  1. 1.0 1.1 Perry M, Delarche A, Ribes D, Vergez F, Guilbeau-Frugier C, Laurent C; et al. (2014). "Rituximab-cyclophosphamide-dexamethasone is highly effective in patients with monoclonal Ig deposit-related glomerulopathy and indolent non-Hodgkin lymphomas". Am J Hematol. 89 (10): 969–73. doi:10.1002/ajh.23798. PMID 25043930.
  2. 2.0 2.1 Michallet AS, Rossignol J, Cazin B, Ysebaert L (2011). "Rituximab-cyclophosphamide-dexamethasone combination in management of autoimmune cytopenias associated with chronic lymphocytic leukemia". Leuk Lymphoma. 52 (7): 1401–3. doi:10.3109/10428194.2011.591005. PMID 21699387.